IHH Healthcare, a hospital group headquartered in Malaysia, has reached out to its largest shareholder, Mitsui, to assist in discussions with Japanese drugmaker Daiichi Sankyo amid a significant legal dispute involving ₹11,800 crore in damages. The ongoing conflict is rooted in Daiichi's fallout with the Singh brothers, leading to legal actions in both Indian and Japanese courts. IHH's group CEO, Prem Kumar Nair, indicated a willingness to explore out-of-court negotiations, signaling the company's desire to resolve the matter amicably. Despite the litigation, IHH remains focused on its operational goals, with Ashok Pandit, the group's chief corporate officer, asserting that the dispute does not distract from their business objectives. Both executives emphasized their commitment to following the legal process while being open to potential negotiations, reflecting a rational approach to the situation. The ongoing court proceedings in the Delhi High Court are expected to shape the next steps for IHH as they navigate this complex legal landscape.